Abstract 213P
Background
Lifestyle, environmental or mood factors may influence cancer outcomes. To harness these complex data for clinical decision-making, we propose building a PDT using a multidimensional and longitudinal data capture approach in prevalent cancers. We report the feasibility at the 10% planned accrual (N=30/300).
Methods
Prospective, multicentric (n=9) observational study. Inclusion criteria: treatment-naïve women >18 y.o. with metastatic lung or colorectal cancer eligible for any first-line treatment or hormone-positive breast cancer eligible for first-line endocrine + CDK4/6 inhibitor. Patients are profiled at baseline (V1), 1 month (m; V2), 3m (V3), and every 3m (V4…Vn), including an e-CRF with 24 clinical, 18 demographic, and 96 bloodwork fields; body CT; plasma (Pl) metabolomics and proteomics, germline methylome, stool (St) metabolomics and metagenomics; and V1 tumor (T) and germline genomics. Continuous physiological monitoring is captured via smartwatch (HR, pO2, sleep, activity). EORTCQ30, GH28, PRO-CTCAE and diet PDAQ questionnaires V1 to Vn, spontaneous reporting of emotional states (from a list of 20), and pain (VAS, daily) are captured via App. Coverage is computed as % of obtained vs. planned data. Sample quality is assessed based on pre-established QC parameters.
Results
N=30 pts (14 breast, 12 lung, 4 colon). Median(range) time on study: 202 days (2-350 d): 4 pts for > 9 m, 25 for >6 m and 29 for >4m. Clinical and analytical fields completed at 86%, and 93% (V1); 89% and 96% (V2); 81% and 93% (V3); 74% and 78% (V4); 100% and 100% (V5). Samples: V1: 93% T, 100% Pl and 80% St; V2: 100% Pl, 82% St; V3: 92% Pl, 78% St; V4: 87% Pl, 61% St; V5: 100% Pl, 100% St samples were obtained. 100% T, Pl and St samples met DNA QC criteria, yielding 11.9 (0.29-70), 10.2 (0.4-59) and 9.0 (1.5-27) ug of DNA, respectively. 100% samples for methylomics and metabolomics met 5 and 4 QC criteria respectively. Physiologic monitoring captured 94%, 83%, 69% and 63% of the maximum expected activity, HR, pO2 and sleep quality data. 90% and 93% of ptes entered >1 emotion (median 0.56/day) and pain data (median 0.53/day). 250 of 328 (76%) planned questionnaires were filled.
Conclusions
High patient engagement and data/sample quality affirm the feasibility of constructing a PDT.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Centro Nacional de Investigaciones Oncologicas (CNIO), Madrid, Spain.
Funding
Centro Nacional de Investigaciones Oncologicas (CNIO), Madrid, Spain.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
826P - Efficacy of non-doxorubicin based regimens in severely G6PD deficient patients with DLBCL
Presenter: Shruti Prem Sudha
Session: Poster session 09
827P - Comparison of efficacy and safety between glofitamab and real-world regimens among Chinese patients with 3L+ relapsed/refractory diffuse large B-cell lymphoma: An external control study
Presenter: Keshu Zhou
Session: Poster session 09
828P - Translocation 11;14 is not associated with adverse prognosis in the era of novel anti-myeloma therapeutics
Presenter: Ioannis Ntanasis-Stathopoulos
Session: Poster session 09
829P - Flumatinib combined with chemotherapy for newly diagnosed adult with Ph-positive acute lymphoblastic leukemia: A single-center, retrospective observational study
Presenter: HAN SHUYU
Session: Poster session 09
830P - Prognostic model of pediatric AML patients with RUNX1-RUNX1T1 fusion gene
Presenter: Yang Xun
Session: Poster session 09
Resources:
Abstract
831P - Impact of chronic kidney disease on disease outcomes in hospitalized multiple myeloma patients: A National inpatient sample study from 2016 to 2020
Presenter: Marco Bermudez
Session: Poster session 09
Resources:
Abstract
832P - CLOMB: A validated scoring model to predict the relapse in the central nervous system of pediatric acute B-cell lymphoblastic leukemia
Presenter: Jiacheng Li
Session: Poster session 09
Resources:
Abstract
833P - Latest results of GVM±R regimen for the salvage therapy of patients with relapsed or refractory aggressive non-Hodgkin's lymphoma
Presenter: Wei Liu
Session: Poster session 09
834P - Treatment of DLBCL in HIV patient: Still a dilemma
Presenter: Devashish Desai
Session: Poster session 09
835P - Genetic, epigenetic, and clinical significance of Wilms’ tumor 1 (WT1) gene in acute myeloid leukemia
Presenter: Harsh Goel
Session: Poster session 09
Resources:
Abstract